Nosratabadi Mohsen, Akhtari Javad, Faeli Leila, Haghani Iman, Aghili Seyed Reza, Shokohi Tahereh, Hedayati Mohammad Taghi, Zarrinfar Hossein, Mohammadi Rasoul, Najafzadeh Mohammad Javad, Khodavaisy Sadegh, Al-Harrasi Ahmed, Javan-Nikkhah Mohammad, Kachuei Reza, Salimi Maryam, Fattahi Mahsa, Badali Hamid, Al Hatmi Abdullah M S, Abastabar Mahdi
Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari 4816983663, Iran.
Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari 4816983663, Iran.
J Fungi (Basel). 2022 Jul 4;8(7):709. doi: 10.3390/jof8070709.
species are filamentous fungi that cause a variety of infections in humans. Because they are commonly resistant to many antifungal drugs currently available in clinical settings, research into alternative targets in fungal cells and therapeutic approaches is required. The antifungal activity of miltefosine and four comparators, amphotericin B, voriconazole, itraconazole, and caspofungin, were tested in vitro against a collection of susceptible and resistant clinical ( = 68) and environmental ( = 42) isolates. Amphotericin B (0.8 μg/mL) had the lowest geometric mean (GM) MICs/MECs values followed by miltefosine (1.44 μg/mL), voriconazole (2.15 μg/mL), caspofungin (7.23 μg/mL), and itraconazole (14.19 μg/mL). Miltefosine was the most effective agent against isolates after amphotericin B indicating that miltefosine has the potential to be studied as a novel treatment for infections.
该菌种是丝状真菌,可导致人类多种感染。由于它们通常对临床环境中目前可用的许多抗真菌药物具有抗性,因此需要对真菌细胞中的替代靶点和治疗方法进行研究。在体外测试了米替福新和四种对照药物两性霉素B、伏立康唑、伊曲康唑和卡泊芬净对一组敏感和耐药的临床(n = 68)和环境(n = 42)分离株的抗真菌活性。两性霉素B(0.8μg/mL)的几何平均(GM)最低抑菌浓度/最低有效浓度值,其次是米替福新(1.44μg/mL)、伏立康唑(2.15μg/mL)、卡泊芬净(7.23μg/mL)和伊曲康唑(14.19μg/mL)。米替福新是仅次于两性霉素B的对分离株最有效的药物,这表明米替福新有潜力作为一种新型治疗方法用于该菌种感染的研究。